Rival BTK degraders face off in CLL patients naive to BTK inhibition.
ApexOnco Front Page
Recent articles
Talvey looks good with Darzalex in the second line, while Pomalyst’s role is less clear.
The first case reports with the group’s lead Car-T therapy, plus talk of autoimmune diseases and diabetes, prompt a 39% share price surge.
Several companies have followed Pfizer into CDK2 inhibitor development, but the jury is out on this field’s promise.
A $680m swoop for Harpoon will fill a hole in Merck’s pipeline.
Ambrx’s PSMA-targeting ADC generated puzzling data at ESMO, but J&J has seen enough to launch a premium-priced buyout.
Allogene joins Adicet in going back to the drawing board and scrapping trials in late-line aggressive lymphoma.
The German group hopes to expand its colorectal cancer offering, taking on the only SLC6A8 inhibitor in development.